Morten Munk Fujifilm Diosynth Biotechnologies

One common denominator for his work has been to use his business and quality mindset in combination with a broad perspective on biomanufacturing, to support all stages of development and the full supply chain of high-quality pharmaceuticals. This includes experience in addressing the areas critical for commercial manufacturing during the process development and subsequent scale-up stages, as well as handling drug product operations and distribution aspects.

Morten joined FUJIFILM Diosynth Biotechnologies (FDB) in 2020 as Alliance Manager, supporting the strategic partnership with several FDB’s key partners. Prior to this position and since 2015 he held a role as Global Technology Partner, supporting all aspects around biopharmaceutical development and manufacturing. In 2001 he co-founded CMC Biologics (now AGC Biologics), where he held a position as Vice President for Operations and later Business Development. Prior to founding CMC Biologics, Morten held a position as Principal Scientist at Novo Nordisk A/S which include being Project Manager for the CMC part of several projects, which have been commercialized successfully, including development of the blockbuster insulin analogue, named Levemir / Detemir.

Furthermore, Morten has authored or co-authored several technical articles and guidelines. Due to his technology expertise coupled with thorough business understanding, Morten is frequently invited to give scientific and technical presentations at international conferences. In addition, Morten is active in the biopharmaceutical community as member of scientific committees for various international conferences and as volunteer in international industry organizations such as PDA, ISPE and BPOG. Moreover, Morten is chair of PDA Biotechnology Advisory Board, and member of the Advisory Board for Master studies at Copenhagen University.